Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches - Takeaways - MDSpire

Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches

  • By

  • Yilei Cui

  • Chun-Chun Gau

  • Chuang-Wei Wang

  • Chun-Bing Chen

  • Wen-Hung Chung

  • Gary J. Fisher

  • Sung Won Choi

  • June 9, 2026

  • 0 min

Share

  • 1

    Graft-versus-host disease (GVHD) is a major cause of non-relapse mortality following allogeneic hematopoietic stem cell transplantation (HSCT).

  • 2

    Acute GVHD affects multiple organs and can progress to chronic GVHD, leading to significant long-term morbidity and mortality.

  • 3

    Recent advancements include the ST2/REG3α MAGIC biomarker panel and novel B-cell subsets for improved diagnostics and risk stratification.

  • 4

    GVHD affects 40%-60% of HSCT recipients, with severe cases linked to worse outcomes and increased mortality rates.

  • 5

    Current therapeutic strategies focus on prophylaxis and treatments for steroid-refractory disease, addressing ongoing challenges in GVHD management.

Original Source(s)

Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches

  • by Yilei Cui, Chun-Chun Gau, Chuang-Wei Wang, Chun-Bing Chen, Wen-Hung Chung, Gary J. Fisher, Sung Won Choi

  • June 9, 2026

Related Content

Case Report: Post-transplant lymphoproliferative disorder mimicking Baló’s concentric sclerosis

Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise

Survival trends in the era of novel therapies identify unmet needs in peripheral T-cell lymphoma: a national cancer database analysis